


Patent Claims


1. Use of a compound of the general formula I



wherein:

$n = 1-5$;


$R2 = OA$; $R3$ and $R4$ are each independently selected from H and OA; with A being selected from H, C1-3 alkyl or a group



in which $R6$ and $R7$ are each independently alkyl or aryl;

$R5$ is a C1-3 alkyl;

$R1$ is a group selected from hydrogen, 3-pyridyl, 4-pyridyl, optionally substituted phenyl,




wherein X is selected from S, O or NH;

wherein the compound of formula I is present as racemate or as a pure (R)- or (S)-enantiomer;

as well as physiologically acceptable salts of these compounds, for the preparation of a medicament for the treatment of depression.


2. Use according to claim 1, wherein $R3$ and $R4 = H$.

3. Use according to one of the preceding claims, wherein A is a hydrogen atom or a group



in which R6 is C1-12 alkyl, phenyl or methoxyphenyl.

4. Use according to one of the preceding claims, wherein n = 1-3 and R5 is a C3 alkyl.
5. Use according to one of the preceding claims, wherein R1 is selected from the group



wherein X is S, O or NH.


6. Use according to one of the preceding claims, wherein X is a sulphur atom.
7. Use according to one of the preceding claims, wherein R1 is a 2-thienyl.
8. Use according to one of the preceding claims, wherein the compound is 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthol.
9. Use according to claim 8, wherein the compound is the pure (S)-enantiomer (rotigotine).
10. Use according to one of the preceding claims, wherein the depression is a unipolar depression [major depression] or a depressive phase of a manic-depressive disorder.
11. Use according to one of the preceding claims, wherein the depression is an organic depression.
12. Use according to one of the preceding claims, wherein the depression is an organic depression not associated with Parkinson's disease.
13. Use according to one of the preceding claims, wherein the depression is a depression associated with Parkinson's disease.
14. Use according to one of the preceding claims, wherein the medicament is provided for parenteral, transdermal or mucosal administration.
15. Use according to one of the preceding claims, wherein the compound of general formula I is administered in a dose of 0.5 to 50 mg per day.
16. Combination preparation for the treatment of depression, comprising a compound

according to one of claims 1 to 9 and a further active ingredient from the group of antidepressants, antipsychotics, sedatives, anxiolytics or anti-migraine agents.

17. Method for the treatment of depression in a mammal, comprising the administration of a therapeutically effective amount of a compound of formula I, as defined in claims 1 to 9, to said mammal.

Patent Claims


1. Use of a compound of the general formula I



wherein:

$n = 1-5$;


$R2 = OA$; $R3$ and $R4$ are each independently selected from H and OA ; with A being selected from H, C1-3 alkyl or a group



in which $R6$ and $R7$ are each independently alkyl or aryl;

$R5$ is a C1-3 alkyl;

$R1$ is a group selected from




wherein X is selected from S, O or NH;

wherein the compound of formula I is present as racemate or as a pure (R)- or (S)-enantiomer;

as well as physiologically acceptable salts of these compounds, for the preparation of a medicament for the treatment of endogenous depression or of organic depressions not associated with Parkinson's disease.

2. Use according to claim 1, wherein $R3$ and $R4$ are both respectively hydrogen.
3. Use according to one of the preceding claims, wherein A is a hydrogen atom or a group



in which $R6$ is C1-12 alkyl, phenyl or methoxyphenyl.

4. Use according to one of the preceding claims, wherein n has a value of 1-3 and R5 is a C3 alkyl.
5. Use according to one of the preceding claims, wherein X is a sulphur atom.
6. Use according to one of the preceding claims, wherein R1 is a 2-thienyl.
7. Use according to one of the preceding claims, wherein the compound is 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthol.
8. Use according to claim 7, wherein the compound is the pure (S)-enantiomer (rotigotine).
9. Use according to one of the preceding claims, wherein the depression is a unipolar depression [major depression] or a depressive phase of a manic-depressive disorder.
10. Use according to one of the preceding claims, wherein the depression is an organic depression.
11. Use according to one of the preceding claims, wherein the medicament is provided for parenteral, transdermal or mucosal administration.
12. Use according to one of the preceding claims, wherein the compound of general formula I is administered in a dose of 0.5 to 50 mg per day.
13. Combination preparation for the treatment of depression, comprising a compound according to one of claims 1 to 8 and a further active ingredient from the group of
 - antidepressants, selected from the group of selective serotonin reuptake inhibitors, mixed serotonin-, noradrenaline reuptake inhibitors, selective noradrenaline reuptake inhibitors, monoaminoxidase inhibitors, alpha2-receptors and/or serotonin receptor-modulators, adenosine antagonists, sigma-opioid receptor ligands, NK antagonists, melatonin agonists or modulators of the hypothalamus-hypophysis-adrenal axis;
 - antipsychotics, selected from promethazine, fluphenazine, perphenazine, levomepromazine, thioridazine, perazine, promazine, chlorprothixene, zuclopenthixol, prothipendyl, flupentixol, zotepine, benperidol, pipamperone, melperone, haloperidol, bromperidol, sulpiride, clozapine, pimozide, risperidone, quetiapine, amisulpride, olanzapine;
 - sedatives, selected from diphenhydramine, doxylamine succinate, nitrazepam,

midazolam, lorazepam, flunitrazepam, flurazepam, oxazepam, bromazepam, triazolam, brotizolam, temazepam, chloral hydrate, zopiclone, zolpidem, tryptophan, zaleplon;

- anxiolytics, selected from fluspirilene, thioridazine, oxazepam, alprazolam, bromazepam, lorazepam, prazepam, diazepam, clobazam, medazepam, chlordiazepoxide, dipotassium chlorazepate, nordazepam, meprobamate, buspirone, kavain, hydroxyzine;

or

- anti-migraine agents, selected from almotriptan, zolmitriptan, acetylsalicylic acid, ergotamine, dihydroergotamine, methysergide, ipرازochrome, ibuprofen, sumatriptan, rizatriptan, naratriptan, paracetamol.

14. Method for the treatment of depression in a mammal, comprising the administration of a therapeutically effective amount of a compound of formula I, as defined in claims 1 to 8, to said mammal.